The observed reductions in NT-proBNP in DEFINE-HF and EMPULSE, together with the robust reverse remodeling documented in EMPA-TROPISM, provide converging evidence that SGLT2 inhibitors exert meaningful hemodynamic and myocardial effects beyond glycemic control. The gene discussed is NPPB; the disease is hydrops fetalis.